Nidec Announces the Status of Own Share Repurchase
Oct 02, 2017 06:30 am UTC| Business
KYOTO, Japan, Oct. 02, 2017 -- Nidec Corporation (TSE:6594) (OTC US:NJDCY) (the “Company”) today announced the status of the Company’s own share repurchase under its ongoing repurchase plan resolved at a meeting of the...
1,3-Butylene Glycol (1,3-BG) Market to Reach 38,939.5 MT by 2023: P&S Market Research
Oct 02, 2017 06:30 am UTC| Business
NEW YORK, Oct. 02, 2017 -- According to new market research report titled “1,3-Butylene Glycol (1,3-BG) Market by Product (Pharmaceutical Grade, Industrial Grade), by Application (Cosmetic Personal Care Products, Food...
CGG: announces overwhelming acceptance by creditors entitled to vote on the chapter 11 plan
Oct 02, 2017 05:31 am UTC| Business
CGG announces overwhelming acceptance by creditors entitled to vote on the chapter 11 plan Paris, France - October 2, 2017 CGG SA announces that all creditor classes entitled to vote on the chapter 11 plan...
Norsk Hydro - Acquisition of Sapa completed
Oct 02, 2017 05:16 am UTC| Business
Norsk Hydro's acquisition of Orkla's 50% ownership in Sapa was completed today, October 2, giving Hydro full ownership in the global leader in extruded aluminium solutions and making Hydro a leading force in the global...
TiGenix to host Analyst and Investor Event in New York City
Oct 02, 2017 05:03 am UTC| Business
PRESS RELEASE TiGenix to host Analyst and Investor Event in New York City Leuven (BELGIUM) - October 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company...
BONDUELLE - 2016-2017 Annual Results: a key milestone in the VegeGo! 2025's ambition
Oct 02, 2017 05:03 am UTC| Business
BONDUELLE A French SCA (Partnership Limited by Shares) with a capital of 56,000,000 Euros Head Offices: La Woestyne 59173 Renescure, France Business registration number: 447 250 044 (Dunkerque Registrar of...
Oct 02, 2017 05:03 am UTC| Business
REGULATED INFORMATION - INSIDE INFORMATION Caplacizumab meets primary endpoint and key secondary endpoints Statistically significant reduction in time to platelet count response, with at any given time patients...